Depomed (DEPO) Misses Q1 EPS by 7c; Guides Below
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value
May 9, 2017 4:02 PM EDT- First Quarter GAAP Revenues of $90 million, non-GAAP Revenues of $95 million -- Company Announces Implementation of Strategic Initiatives to Drive Portfolio Growth -- 2017 Non-GAAP Revenue Guidance of $410 to $430 million Inclusive of an Expected Wholesaler Inventory Reduction -- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -
NEWARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended March 31, 2017 and outlined a set of strategic initiatives aimed at positioning the Company for future growth.
I am excited to have joined Depomed... More
